Recent Articles

• 
  AI Healthcare

  SK Biopharm, Emory Med School Partner on EEG Digital Health Expansion

  SK Biopharmaceuticals announced on the 17th that it will expand into the EEG (electroencephalogram)-based digital healthcare domain, as it begins joint AI research with Emory University School of Medicine in the United States through its joint venture, Mantis Care, to detect and predict epileptic se

  2026.03.17
• 
  Celltrion

  Celltrion Signs KRW 380 Billion CMO Deal, Q1 Orders Top KRW 1 Trillion

  Celltrion announced on the 17th that it has signed a contract manufacturing organization (CMO) agreement with a global pharmaceutical company for the production of biopharmaceutical drug substances (DS, Drug Substance). Due to business confidentiality, the company decided not to disclose the name of

  2026.03.17
• 
  Medical / Drug Development

  Samsung Bioepis to Develop G2G Bio Obesity Drug

  Kim Kyung-ah, President of Samsung Bioepis (center), Hong Sung-won, CEO and Executive Vice President of Episnext Lab (left), and Lee Hee-yong, CEO of G2GBIO, pose for a commemorative photo after signing a joint development and licensing agreement for an obesity treatment. Bio holding company Samsung

  2026.03.16
• 
  Samsung Bioepis

  Samsung Bioepis Makes Big Bet on Obesity Drug

  Kim Kyung-ah, President of Samsung Bioepis (center), Hong Sung-won, Executive Vice President (left, CEO of Epis Nexlab), and Lee Hee-yong, CEO of G2GBIO, sign an agreement for joint development of new biological drugs and a technology platform and pose for a commemorative photo. Provided by Samsung

  2026.03.16
• 
  Global Expansion

  Celltrion Cancer Drug Keeps Japan Lead; New Launch

  Celltrion announced on the 16th that its oncology biosimilar products are continuing to hold the No. 1 market share in Japan.According to pharmaceutical market research firm IQVIA and local data, as of December last year, the market share in Japan of metastatic colorectal cancer and breast cancer tr

  2026.03.16
• 
  Biopharma

  DongKook Pharma Shifts From Drugmaker to Healthcare Firm

  DongKook Pharmaceutical headquarters DongKook Pharmaceutical’s business structure has been changing in recent years. The company has long been known as a pharmaceutical firm centered on over-the-counter (OTC) brands such as Insadol and Madecassol, but it has recently begun to parallelly operate heal

  2026.03.13
• 
  Celltrion

  US Biosimilar Rule Easing Seen Boosting Celltrion

  Celltrion announced on the 13th that it will immediately reflect global regulators’ relaxed policies on biosimilar development in its ongoing pipeline, aiming to reduce development costs and shorten timelines.The U.S. Food and Drug Administration (FDA) recently released the fourth revised draft of i

  2026.03.13
• 
  AI Healthcare

  Daewoong Pharma: MobiCare Wearable ECG Enables Early AF Detection

  Medical staff at the Gyeongnam branch of the Korea Association of Health Promotion apply the wearable electrocardiogram device “mobiCARE” to a patient. Daewoong Pharmaceutical Daewoong Pharmaceutical announced on the 12th that its wearable electrocardiogram (ECG) testing solution “mobiCARE” has succ

  2026.03.12
• 
  Biopharma

  Alteogen Wins US Patent for Keytruda, Qurex Formulation

  Alteogen headquarters and research center Bioplatform company Alteogen announced on the 12th that it has registered with the United States Patent and Trademark Office (USPTO) a composition patent related to the subcutaneous formulation of Keytruda that combines its Hybrozyme platform-based ALT-B4 (i

  2026.03.12
• 
  Global Expansion

  Korean United Pharma Expands in Mongolia With Cancer Drugs

  Korea United Pharm is accelerating efforts to expand its market share in Mongolia by broadening contact points with local partners. The company announced on the 12th that it had invited GanEm Pharma, a Mongolian distribution company, on the 9th to discuss business strategies for boosting exports. Th

  2026.03.12